ASCO Annual Meeting: Breast Cancer | Conference

Sara A. Hurvitz, MD, Discusses Outcomes With Sacituzumab Govitecan By Age for Metastatic Triple-Negative Breast Cancer
August 07, 2021

CancerNetwork® sat down with Sara A. Hurvitz, MD, at the 2021 ASCO Annual Meeting to talk about multidisciplinary care with geriatrician oncologists and the use of age-based analyses for diagnosis and following up of metastatic triple-negative breast cancer.

Sacituzumab Govitecan for Metastatic TNBC Retains Survival Advantage Over Chemotherapy
June 08, 2021

Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician's choice chemotherapy.

Numerically Improved pCR Not Significant With SD-101 Plus Pembrolizumab in HER2– Breast Cancer
June 07, 2021

Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.

Ultralow Risk 70-Gene Signature May Indicate Survival Outcomes in Early-Stage Breast Cancer
June 06, 2021

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.

Neoadjuvant Durvalumab Plus Chemotherapy Effective in Early-Stage TNBC
June 06, 2021

Phase 2 results presented during the 2021 ASCO Annual Meeting suggest durvalumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer may be beneficial in certain patients.

De-escalated Neoadjuvant Trastuzumab/Pertuzumab Induced Sufficient Responses in HER2+/HR– Breast Cancer
June 06, 2021

With a de-escalation strategy for administration of trastuzumab and pertuzumab in the neoadjuvant setting, patients with HER2-positive, hormone receptor–negative breast cancer experienced high rates of response and survival.

Ribociclib Plus Fulvestrant Continued to Improve OS in Advanced, HR+ Breast Cancer, Regardless of Setting
June 05, 2021

Ribociclib (Kisqali) plus fulvestrant (Faslodex) maintained significantly improved overall survival (OS) rates after nearly 5 years of follow-up compared to fulvestrant alone in postmenopausal patients who had hormone receptor (HR)-postivie, HER2-negative advanced breast cancer.

Venetoclax Plus Fulvestrant Did Not Improve Outcomes Compared to Fulvestrant Alone in ER+/HER2- Breast Cancer
June 05, 2021

Venetoclax plus fulvestrant did not result in better outcomes compared to fulvestrant alone in previously treated patients who had locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Palbociclib Plus Fulvestrant Combo Maintains Long-Term OS Benefit
June 05, 2021

Palbociclib plus fulvestrant maintained a clinically meaningful overall survival improvement compared to placebo plus fulvestrant after a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.

Efficacy Elicited From Olaparib in BRCA1/2+, HER2– Early Breast Cancer Persists 1 Year After Standard Treatment
June 03, 2021

Data from the OlympiA trial support olaparib use in certain patients with BRCA1/2–positive early breast cancer.